Finanzen von Dyadic International Inc (DYAI)DYAIDyadic International Inc

Dyadic International Inc (DYAI) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is United states-Operating, accounting for 79.9% of total sales, equivalent to $2.15M. Other significant revenue streams include Netherlands-Operating and Eliminations-Oprating. Understanding this composition is critical for investors evaluating how DYAI navigates market cycles within the Biotechnology & Medical Research industry.

Evaluating the bottom line, Dyadic International Inc maintains a gross margin of -2.40%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -212.82%, while the net margin is -220.98%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively DYAI converts its operational activities into shareholder value.

In the context of the broader market, DYAI competes directly with industry leaders such as CCM and RADX. With a market capitalization of $31.05M, it holds a significant position in the sector. When comparing efficiency, DYAI's gross margin of -2.40% stands against CCM's -2.13% and RADX's N/A. Such benchmarking helps identify whether Dyadic International Inc is trading at a premium or discount relative to its financial performance.

The financial performance shows a troubling trend with net income losses exceeding 2 million USD in recent quarters. The gross margin has also turned negative at -2.40% in Q2 2026, indicating operational challenges.